Table 1.

Clinical and pathological characteristics associated with seizure control in diffuse astrocytic and oligodendroglial tumors

	Well-controlled group (Engel Class I, II)	Drug-resistant group (Engel Class III, IV)	P-value
Number	14	13
Age	43.5 (33.8–58.3)	32.0 (21.0–42.5)	0.038
Sex (men/women)	5/9	8/5	0.180
Origin (frontal/temporal/other)	7/6/1	6/4/3	0.486
Existence of preoperative seizure (−/+)	2/12	4/9	0.385
Extent of tumor removal (<95% or ≥95%)	4/10	4/9	1.000
Temozolomide (−/+)	5/9	4/9	1.000
Radiation (−/+)	10/4	7/6	0.440
Tumor volume after treatment (<50% or ≥50%)	11/3	6/7	0.081
Recurrence (−/+)	10/4	6/7	0.182
Neurological symptoms (−/+)	13/1	7/6	0.021
Karnofsky Performance Scale	90.0 (90.0–100.0)	90.0 (40–100.0)	0.375
IDH-1 (−/+)	2/12	5/8	0.209
1p/19q co-deletion (−/+)	6/8	11/2	0.046
Olig2 (−/+)	6/8	10/3	0.072
PDGFR-α (−/+)	6/8	6/7	0.863
p53 (−/+)	9/5	1/12	0.004
ATRX (−/+)	8/6	8/5	0.816
Ki67 (<5/≥5)	8/6	7/6	0.863

P <0.05 was considered to be indicative of statistical significance.